CERo Therapeutics Soars 12.36% on Breast Cancer Drug Success

CERo Therapeutics' stock surged 12.36% in pre-market trading on June 2, 2025, driven by the positive results of its breast cancer drug, which showed a 2.9-month improvement in median progression-free survival compared to fulvestrant in ESR1-mutant, ER+/HER2- breast cancer patients.

CERo Therapeutics' breast cancer drug, vepdegestrant, has shown significant improvements in progression-free survival (PFS) for patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer. The drug reduced the risk of disease progression or death by 43% compared to fulvestrant, as demonstrated in the pivotal Phase 3 VERITAC-2 clinical trial presented at ASCO. This trial also showed a 2.9-month improvement in median PFS, highlighting the drug's potential as a new standard of care for this patient population.

The positive results from the VERITAC-2 trial have positioned CERo Therapeutics as a key player in the breast cancer treatment landscape. The drug's efficacy in reducing disease progression and improving PFS has generated significant interest from investors, contributing to the stock's pre-market surge. The company's focus on developing innovative therapies for breast cancer has been validated by these clinical trial results, which could lead to further advancements in cancer treatment.